, Biochim Biophys Acta. (2008) [14] E2F1 The E2F1 protein functions as a transcription factor that enhances cell proliferation Alonso et al., Cancer Lett. (2008) [15] HSP90 Cell proliferation and/or survival Workman et al., Ann N Y Acad Sci. (2007) [16] Bcr-Abl Chemosensitivity to imatinib Chen et al., Cancer Res. (2006) [17] mTOR mTOR plays a Protein Tyrosine Kinase inhibitor central role in cell growth, proliferation and survival Choo et al., Cancer Cell. (2006) [18] microRNA-21 Overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype Medina et al., Nature. (2010) [19] Oncogene addiction in gliomas Glioma is the most common primary brain tumor in adults

with poor prognosis [20]. The clinical outcomes of patients with glioma traditionally depend upon the tumor pathological grade. But the patients even within the same grade usually have diverse prognosis and therapeutic outcomes [21]. Over the last Selleck RG7420 decade, the knowledge on the molecular genetic background of human gliomas has dramatically increased [22]. However, differences in glioma genetics may result in distinct prognosis and therapeutic outcome, and the underlying mechanism has not been clarified systematically. Underscoring genetic aberrations in gliomas will enhance understanding of tumor biology and have significant

clinical relevance for treatment. However, amounts of chromosomal alterations and cancer-causing mutations A-1210477 mw Florfenicol have been discovered through genome-scale approaches. The complex genetic aberrations provide the basis for molecular targeted therapies, and molecular tests serve to complement the subjective nature of histopathologic criteria and add useful data regarding patient prognosis and therapeutic outcome. Oncogene addiction hides in the above background with complex genetic

aberrations. Different types of oncogene addiction can dictate distinct glioma subtypes. It becomes a promising direction to define oncogene addiction for molecular targeted therapy in gliomas. At present, only few oncogene addictions have been identified in gliomas except for E2F1 addiction [15], and some classical glioma-associated genes may be potential oncogene addictions. EGFR gene amplification or overexpression is a particularly striking feature of glioblastoma (GBM), observed in approximately 40% of tumors. In nearly 50% of tumors with EGFR amplification, a specific EGFR mutant (EGFRvIII) can be detected [23]. This mutant is highly oncogenic and is generated from a deletion of exons 2 to 7 of the EGFR gene, which results in an in-frame deletion of 267 amino acids from the extracellular domain of the receptor. EGFRvIII is unable to bind ligand, and it signals constitutively. Although EGFRvIII has the same signaling domain as the wild-type receptor, it seems to generate a distinct set of downstream signals that may contribute to an increased tumorigenicity [24].